ExpressionEdits: Revolutionizing Protein Expression in Biotechnology Industry
ExpressionEdits, a biotechnology company based in Cambridge, UK, is making waves in the industry with its innovative approach to optimizing protein expression. Led by Dr. Kärt Tomberg, Dr. Leopold Parts, and Dr. Rebecca Godfrey, the company recently secured $13M in Seed funding, with support from investors like Octopus Ventures, redalpine, and BlueYard Capital. With this funding, ExpressionEdits plans to advance candidate selection for preclinical studies and develop a robust pipeline of protein-based therapeutics.
Founded in 2021, ExpressionEdits is at the forefront of biotechnology, thanks to its proprietary intronization technology for gene design.
The company's Genetic Syntax Engine utilizes advanced AI and deep biological insights to predict and redesign genes, enhancing protein expression levels for various therapeutic applications. By mimicking the natural genetic landscape with their technology, ExpressionEdits aims to improve the efficacy and precision of gene therapies, ultimately reducing toxicity and expanding the targeting capabilities of specific tissues.
The focus of ExpressionEdits' pipeline will be on recombinant proteins that have historically faced challenges in production and manufacturing. By leveraging their cutting-edge technology and expertise, the company is poised to revolutionize the field of biotechnology and set new standards for protein expression optimization. With a talented team of founders and a strong network of investors, ExpressionEdits is well-positioned to drive innovation and make a significant impact in the biotech sector.
They've invested in ExpressionEdits
Get to know these Biotech investors
Click here for a full list of 6,528+ startup investors in the UK